Piramal Pharma Ltd News

Piramal Pharma flags early recovery signs in CDMO demand as Q3 loss widens

The company attributed the weaker performance largely to continued inventory destocking in one of its large on-patent commercial products, affecting its CDMO business

Piramal Pharma shares gain 4% on Q3 results; check key highlights inside

Following the results announcement, the company's share price rose 3.78 per cent to log an intraday high of ₹159.79 per share

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

Stocks to watch, Dec 12: Tata Power, Astra Microwave, NBCC, Vedanta, Honasa

Stocks to watch today, December 12: Piramal Pharma, Kansai Nerolac and Oswal Pumps are other top stocks to track today.

InCred Equities sees 41% upside in Piramal Pharma; initiates 'Buy'

Year-to-date (Y-T-D), Piramal Pharma shares have lost 23 per cent, as compared to Sensex's rise of 5 per cent

Jefferies upbeat on India CRDMO; initiates Buy on Cohance; upgrades Divi's

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details

Smallcap, midcap stocks dip; here's why broader markets are down

Analysts noted that the central bank's move was more of a non-event for the markets, with uncertainty surrounding tariffs having a greater impact on investor sentiment